Robert Fox
Internal Medicine · San Diego, CANPI 1740305432
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,166 of the $36,184 with a category attached, or 83.4%. 31 manufacturers reported payments, led by Novartis at 31.8% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $304.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$12K
- Kiniksa Pharmaceuticals International, PLC$9K
- GSK$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- AbbVie$1K
- CSL Behring$600
- plus $2K from 25 others
What the payments were for
- Consulting fees$30,16683%
- Travel & lodging$1,2303%
- Food & beverage$4,78813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $11,514 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $8,850 |
| GSK | 4 | $6,750 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $4,935 |
| AbbVie | 24 | $1,205 |
| CSL Behring | 1 | $600 |
| Janssen Scientific Affairs, LLC | 5 | $451 |
| Amgen(2 entities) | 10 | $234 |
| Neurocrine Biosciences, Inc. | 4 | $218 |
| E.r. Squibb & Sons, L.L.C. | 3 | $162 |
| UCB, Inc. | 1 | $131 |
| Lilly USA, LLC | 2 | $130 |
| Pfizer | 4 | $125 |
| Johnson & Johnson | 3 | $106 |
| Impel Pharmaceuticals Inc. | 1 | $104 |
| Kyowa Kirin, Inc. | 1 | $94 |
| AstraZeneca(2 entities) | 3 | $78 |
| Genentech USA, Inc. | 5 | $74 |
| Arbor Pharmaceuticals, Inc. | 3 | $64 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Supernus Pharmaceuticals, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Radius Health, Inc. | 1 | $33 |
| Shire North American Group Inc | 2 | $29 |
| Biogen | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,184 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cevimeline Hcl | 14 | $3,054 |
| Celecoxib | 18 | $1,108 |
| Duloxetine Hcl | 13 | $746 |
| Famotidine | 16 | $168 |
| Gabapentin | 14 | $146 |
| Azithromycin | 14 | $121 |
| Prednisone | 22 | $112 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Diego
- Hatim HusainSan Diego$2M
- Steven EdelmanSan Diego$863K
- Christian RamersSan Diego$675K
- Adam ZweigSan Diego$421K
- James BreitmeyerSan Diego$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Teck LingPalo Alto$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.